Atyr_Logo.png
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
15 nov. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
07 nov. 2024 16h01 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences
31 oct. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences
Atyr_Logo.png
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
08 oct. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Atyr_Logo.png
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02 oct. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Atyr_Logo.png
aTyr Pharma to Participate in September Investor Conferences
21 août 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Participate in September Investor Conferences
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 
13 août 2024 16h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
06 août 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
Atyr_Logo.png
aTyr Pharma Announces Research Study with Stanford Medicine
30 juil. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
Atyr_Logo.png
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03 juin 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”